Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDX Celldex Therapeutics

Trading 08-05 10:01:55 EDT

39.44

+0.39

+0.99%

High39.64	Low38.88	Vol17.51K
Open39.36	D1 Closing39.05	Amplitude1.95%
Mkt Cap3.10B	Tradable Cap2.86B	Total Shares78.49M
T/O688.14K	T/O Rate0.02%	Tradable Shares72.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"Celldex Therapeutics","latestPrice":39.435,"timestamp":1785938508497,"preClose":39.05,"halted":0,"volume":17506,"delay":0,"changeRate":0.009859154929577597,"floatShares":72463400,"shares":78492100,"eps":-4.267422,"marketStatus":"Trading","change":0.385,"latestTime":"08-05 10:01:55 EDT","open":39.36,"high":39.64,"low":38.88,"amount":688135.371264,"amplitude":0.019462,"askPrice":39.62,"askSize":150,"bidPrice":39.04,"bidSize":140,"shortable":3,"etf":0,"ttmEps":-4.267422,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785960000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":39.05,"preHourTrading":{"tag":"盘前","latestPrice":39.5,"preClose":39.05,"latestTime":"08:44 EDT","volume":297,"amount":11590.869609,"timestamp":1785933896889,"change":0.45,"changeRate":0.011524,"amplitude":0.038412},"postHourTrading":{"tag":"盘后","latestPrice":39.05,"preClose":39.05,"latestTime":"19:34 EDT","volume":10092,"amount":394035.26,"timestamp":1785886449064,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.182217,"impliedVol":0.4388,"impliedVolPercentile":0.3904},"requestUrl":"/m/hq/s/CLDX/tweets","defaultTab":"tweets","newsList":[{"id":"2656939645","title":"Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2656939645","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656939645?lang=en_us&edition=fundamental","pubTime":"2026-08-01 03:14","pubTimestamp":1785525255,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) is in focus after releasing topline results from its Phase 2 clinical trial in prurigo nodularis, a development that gives investors new information on a key pipeline program.\nSee our latest analysis for Celldex Therapeutics.\nThe Phase 2 readout arrives after a period of strong momentum in Celldex Therapeutics' stock, with a 90 day share price return of 19.11% and a year to date share price return of 42.48%. The 1 year total shareholder return of 75.09% contrasts...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-after-phase-2-trial-results-as-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-after-phase-2-trial-results-as-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655981255","title":"PharmaCyte Net Loss Widens to $19.42 Million in FY26; Revenue Remains no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2655981255","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655981255?lang=en_us&edition=fundamental","pubTime":"2026-07-30 05:20","pubTimestamp":1785360011,"startTime":"0","endTime":"0","summary":"PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenuePharmaCyte Biotech posted a net loss of USD 19.42 million for fiscal 2026, swinging from net income of USD 30.66 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL4JYXWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655785475","title":"U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal","url":"https://stock-news.laohu8.com/highlight/detail?id=2655785475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655785475?lang=en_us&edition=fundamental","pubTime":"2026-07-29 15:06","pubTimestamp":1785308807,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPalJuly 29 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Boeing, Coca-Cola a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V0KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENPH","BYRE","PPA","ALT","ECL","CFG","ACHC","CNCG","UTES","ABG","CPNG","AMGN","UYG","BCAL","BA","BMED","CHTR","AXTA","GLW","NATO","ABBV","ASH","LEUX","DTE","ASTS","BAC","CSGP","LEU","EBC","CNP","BMRC","ARWR","JDOC","CZR","BE","CLDX","CASY","BRO","CNC","CAKE","DIS","CORZ","ITA","KMX","BIIB","DAR","CLW","CORT","KO","AMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654054554","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654054554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654054554?lang=en_us&edition=fundamental","pubTime":"2026-07-25 22:50","pubTimestamp":1784991019,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Celldex (CLDX) with bullish sent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","XLV","IBRN","PSCH","HCSG","LU0128526141.USD","BK4585","BK4581","ALKS","LABU","LU0029874061.USD","BK4588","MEDX","CLDX","XBI","BK4139","FBT","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653765374","title":"U.S. Stocks on the Move-ge Vernova, Arrowhead Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2653765374","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653765374?lang=en_us&edition=fundamental","pubTime":"2026-07-22 21:55","pubTimestamp":1784728515,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-GE Vernova, Arrowhead PharmaWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nL6N43O0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKDWB100.SGD","LU2129689431.USD","LU2065171311.SGD","IE00B7SZLL34.SGD","LU0203345920.USD","BK4175","IXC","LU0823414551.USD","LU0683600562.USD","GEV","LU0965509010.AUD","LU1084165304.USD","LU1582987597.SGD","LU0211328371.USD","LU2264538146.SGD","LU0052756011.USD","LU2602419157.SGD","IE00B1BXHZ80.USD","LU0861579265.USD","BK4515","LU0859254822.USD","LU0795875086.SGD","LU0654597011.USD","LU0689626769.HKD","LU0882574055.USD","LU0170899867.USD","BK4139","LU0690374615.EUR","LU2347655156.SGD","LU0310800965.SGD","LU0878866978.SGD","BK4550","LU0433182093.SGD","LU0345780950.USD","LU0256331488.USD","LU2133065610.SGD","LU0265550946.USD","LU0265550359.USD","LU0868494708.USD","LU1037948897.HKD","SG9999002521.SGD","LU0612318385.USD","LU0211327993.USD","LU0124676726.USD","GEVX","TEXU","XOMZ","DYN","LU2487616109.SGD","IGE","LU0985489474.SGD","SG9999002232.USD","FTXN","LU0256863811.USD","LU1064131342.USD","LU0630314457.HKD","LU2125154935.USD","LU2357627491.SGD","BK4585","LU1496350171.SGD","LU1778281490.HKD","IE00BFXG1179.USD","DIG","SMCI","CNRG","LU2065169927.USD","SMCY","LU2237438978.USD","LU1496350502.SGD","COR","LU2360032135.SGD","LU1861215975.USD","SGXZ23171101.USD","IE00B19Z3B42.SGD","LU1267930227.SGD","OILT","LU2065170008.USD","LU0545562505.USD","BK4588","LU1037948541.HKD","BK4566","LU0128525689.USD","LU1066051225.USD","LU0426412945.USD","IE00BGHQF524.EUR","POWR","SG9999011175.SGD","LU0098860793.USD","LU2249611893.SGD","LU0724618433.USD","IYZ","LU2430703251.USD","LU0426417589.USD","LU1582987324.SGD","LU0345770993.USD","LU2505996681.GBP","LU0868494617.USD","SMCX","LU0965509101.SGD","LU1228905037.USD","LU2381873111.SGD","LU2168564065.EUR","IYE","LU0124384867.USD","WEEI","TRUI","BK4201","IE00B2Q91V27.USD","LU1489326972.SGD","LU2404859667.USD","LU0278409577.USD","LU2462611646.USD","XLE","LU2098885051.SGD","LU0070217475.USD","LU1169589451.USD","BK4507","IE000M9KFDE8.USD","LU0823414478.USD","BK4598","LU1069347547.HKD","LU1880398554.USD","IE0034235303.USD","BK4182","LU1150488218.USD","LU2430703178.SGD","LU1150488135.SGD","GB00B4LPDJ14.GBP","LU0072461881.USD","LU1116320901.HKD","LU2384288077.EUR","GASZ","LU2168564222.USD","LU0300736492.USD","LU0792757196.USD","LU1718418525.SGD","BK4581","SMCC","BK4516","LU1571399168.USD","LU1674673428.USD","LU2168563687.JPY","LU0788109394.HKD","LU0889566641.SGD","BK4533","LU0266512473.USD","LU0211326839.USD","LU2505996509.AUD","XOM","CAH","BK4212","LU0289739699.SGD","PUI","BK4534","LU1934455194.USD","HK0000914686.HKD","LU2087621335.USD","FSTA","LU0251131958.USD","LU2102340556.USD","LU0122379950.USD","LU0661504455.SGD","LU1169590202.USD","BK4115","LU0787776722.HKD","LU0162691827.USD","SG9999014575.USD","BK4213","LU0994945656.USD","LU1894683348.USD","LU1934455277.USD","LU0154236417.USD","LU2430703095.HKD","CGDG","LU2404859741.USD","LU1883866441.USD","T","LU0320765489.SGD","LU0965508806.USD","CVX","LU0466842654.USD","LU1061106388.HKD","LU0738911758.USD","LU2498475776.HKD","LU0456854461.SGD","SG9999002224.SGD","LU0345770308.USD","HK0000914660.USD","LU1988902786.USD","LU1267930490.SGD","LU2357125470.USD","PM","LU1280957306.USD","LU1032466523.USD","LU1978683503.SGD","LU1303367103.USD","SG9999014559.SGD","TRUO","LU0949170772.SGD","ARWR","BK4170","IE00B1XK9C88.USD","LU0320765646.SGD","FENY","LU0048573561.USD","LU1621768115.EUR","FRNW","LU1267930813.SGD","GB00B4QBRK32.GBP","CLDX","IE0004091025.USD","LU0114720955.EUR","NICO","LU2168564495.EUR","SG9999015341.SGD","LU2294711713.HKD","LU1506573853.SGD","BK4570","LU1585245621.USD","LU2112291526.USD","XLP","LU0432979614.USD","GEVG","LU1983299246.USD","LU0234572021.USD","LU0006061336.USD","SMYY","SG9999014567.USD","EXI","LU2237957902.USD","LU1621768206.USD","DRLL","LU0795875169.SGD","SG9999014542.SGD","LU1093756168.USD","BK4084","LU0742534661.SGD","IE00BSNM7G36.USD","LU1430597077.USD","LU0612318971.USD","CALM","DVN","LU0211326755.USD","LU1430594728.SGD","LU0314106906.USD","BK4592","LU1914381329.SGD","LU1582986433.USD","LU2237957811.SGD","SG9999003800.SGD","JOUL","LU2298322129.HKD","TRUN","LU0912757837.SGD","LU0690374961.EUR","LU1621767810.EUR","BLFS","UXI","LU2468319806.SGD","BK4121","LU0368265418.SGD","LU1839511570.USD","LU1621767737.EUR","SMCL","LU1366192091.USD","LU1674673691.USD","LU2089984988.USD","BK4529","BK4559","LU2543165471.USD","LU0058720904.USD","MCK","IE00BWXC8680.SGD","LU0496365809.HKD","LU0266512127.USD","UGE","LU0070302665.USD","LU0942090050.USD","LU1934455863.HKD","LU1732800096.USD","LU1023059063.AUD","BK4075","LU1929549753.HKD","LU1983260115.SGD","LU0310799852.SGD","IE0002270589.USD","LU2065171402.SGD","LU1732799900.SGD","LU2129689605.HKD","LU1057294990.SGD","GXPE","LU1894683264.USD","LU1116320737.USD","LU2506951792.HKD","LU0208291251.USD","LU2129689514.USD","BK4198","LU0640476718.USD","LU2168564149.EUR","LU1035773651.USD","LU2324357040.USD","LU0068578508.USD","NUKX","LU0965509283.SGD","LU0203347892.USD","RCTR","SMRF","LU1261432733.SGD","OXY","XOMX","XOMO","BK4543","LU0345781412.USD","LU1066051811.HKD","IE00B19Z3581.USD","LU1582986359.USD","LU0149725797.USD","VDE","LU1121112475.USD","LU0300736062.USD","LU1162221912.USD","IE0004086264.USD","OSUR","LU1043141123.HKD","LU2125154778.USD","SG9999015358.SGD","LU1880398471.USD","SG9999004303.SGD","LU1074936037.SGD","BK4505","PXE","LU0210528500.USD","IE00B3CCJ963.GBP","LU1228905540.USD","LU0976567544.SGD","SG9999001440.SGD","LU1861220033.SGD","LU2592432038.USD","LU0122376428.USD","LU0251142724.SGD","LU0053671581.USD","LU1119994496.HKD","ERX","SMCZ","LU1066051498.USD","LU0053666078.USD","LU1043141396.HKD","LU1093756325.SGD","LU0417517546.SGD","LU1814569148.SGD","LU1066053197.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653376342","title":"Celldex Therapeutics Shares Down 2.6% After Scrapping Development of Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653376342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653376342?lang=en_us&edition=fundamental","pubTime":"2026-07-22 21:34","pubTimestamp":1784727271,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653768121","title":"Analysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653768121","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653768121?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:50","pubTimestamp":1784724608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vanda (VNDA) and Celldex (CLDX) with bullish sentime...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-vanda-vnda-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-vanda-vnda-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653075200","title":"Celldex price target lowered to $61 from $67 at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2653075200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653075200?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:35","pubTimestamp":1784720120,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald lowered the firm’s price target on Celldex (CLDX) to $61 from $67 and keeps an Overweight rating on the shares. Celldex’s Phase 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-price-target-lowered-to-61-from-67-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-price-target-lowered-to-61-from-67-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653752199","title":"Celldex Therapeutics is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2653752199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653752199?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:27","pubTimestamp":1784719620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings(END) Dow Jones NewswiresJuly 22, 2026 07:27 ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653575416","title":"Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653575416","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653575416?lang=en_us&edition=fundamental","pubTime":"2026-07-22 18:57","pubTimestamp":1784717842,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila maintained a Buy rating on Celldex yesterday and set a price target of $48.00. The company’s shares closed yester...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653751991","title":"Celldex Therapeutics Inc : Morgan Stanley Cuts Target Price to $40.00 from $44.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2653751991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653751991?lang=en_us&edition=fundamental","pubTime":"2026-07-22 18:36","pubTimestamp":1784716602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nAZN4T9C3L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653249759","title":"Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (OtherPPTDF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653249759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653249759?lang=en_us&edition=fundamental","pubTime":"2026-07-22 18:10","pubTimestamp":1784715040,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (PPTDF) with neutral ratings, indicating th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-celldex-cldx-bristol-myers-squibb-bmy-and-peptidream-otherpptdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-celldex-cldx-bristol-myers-squibb-bmy-and-peptidream-otherpptdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPTDF","LU0128526141.USD","LU0225771236.USD","IHE","LU1430594728.SGD","CLDX","BK4139","LU0237698245.USD","LU0321505868.SGD","LU0321505439.SGD","LU0225284248.USD","LU2125154778.USD","BK4585","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU1291159041.SGD","LU1718418525.SGD","LU2242646821.SGD","LU2242652126.USD","LU2596442595.SGD","LU1868836591.USD","LU1868837136.USD","IE00B2B36J28.USD","XLV","LU0456855351.SGD","LU1585245621.USD","LU0432979614.USD","LU2133065610.SGD","IE0009355771.USD","LU1868836757.USD","LU0306807586.USD","BMY","LU1670711123.USD","FTXH","BK4532","LU1883839398.USD","BK4534","LU0868494617.USD","LU1571399168.USD","LU2360032135.SGD","IE00BJT1NW94.SGD","LU1074936037.SGD","LU1868837300.USD","LU0096364046.USD","LU1093756325.SGD","LABU","LU2125154935.USD","XBI","HCSG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653759328","title":"Celldex Therapeutics Inc : Leerink Partners Cuts Target Price to $70 from $78","url":"https://stock-news.laohu8.com/highlight/detail?id=2653759328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653759328?lang=en_us&edition=fundamental","pubTime":"2026-07-22 18:03","pubTimestamp":1784714639,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0JZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653756521","title":"Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2653756521","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653756521?lang=en_us&edition=fundamental","pubTime":"2026-07-22 17:43","pubTimestamp":1784713394,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) has an average rating of buy and mean price target of $56.73, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653588837","title":"U.s. Research Roundup-danaher, Gm, Msci","url":"https://stock-news.laohu8.com/highlight/detail?id=2653588837","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653588837?lang=en_us&edition=fundamental","pubTime":"2026-07-22 16:07","pubTimestamp":1784707645,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Danaher, GM, MSCIJuly 22 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies, including Danaher, GM and MSCI on Wedn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nL4N43O0M1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPT","ICOI","BOKF","ABT","CLH","CARG","ABBV","SCHW","MO","ALNY","CLX","CSR","AMN","KMX","MMM","DHR","COF","ACVA","AGNG","ADC","CLDX","AKTS","XTN","CALX","CHRW","CVNA","AA","XYZ","ALLY","ICF","BEPC","ADP","COIN","AMT","ANET","CMS","CVLT","CVX","AFL","AAT","CONY","ICRC","IYZ","ALK","CRCL","BNY","VHT","AAOI","FIAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653858427","title":"Celldex Shares Fall After it Drops Skin Disease Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2653858427","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653858427?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:53","pubTimestamp":1784667196,"startTime":"0","endTime":"0","summary":"BUZZ-Celldex shares fall after it drops skin disease drug study** Drug developer Celldex's sharesCLDX.Ofall 6.3% to $33.42 in extended trading** Cosaysit will discontinue development of experimental drug barzolvolimab for prurigo nodularis, a chronic skin disease** Barzolvolimab failed to meet the main goal and key secondary goals in a mid-stage study** As of Tuesday's close, stock has risen ~31% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nL6N43N18G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653826783","title":"Celldex to End Phase 2 Study for Skin-disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2653826783","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653826783?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:23","pubTimestamp":1784665380,"startTime":"0","endTime":"0","summary":"Celldex will discontinue a phase 2 study of a skin-disease treatment after it failed to meet its primary or key secondary endpoints.The treatment, a subcutaneous delivery of barzolvolimab to treat the skin disease prurigo nodularis, did not result in an improvement in itch or skin lesions compared to a placebo, Celldex said Tuesday.Shares fell 6%, to $33.52, in after-hours trading on Tuesday.\"It is disappointing that this study did not confirm the promising signal we observed in the intravenous Phase 1b trial, and that the robust tryptase reductions seen in this study did not result in improvement of PN symptoms for patients who greatly need effective treatments,\" Chief Executive Officer Anthony Marucci said.The company said it continues to evaluate barzolvolimab to treat three other conditions: chronic spontaneous urticaria, symptomatic dermographism and cold urticaria, Marucci said.Write to Elias Schisgall at elias.schisgall@wsj.com Dow Jones NewswiresJuly 21, 2026 16:23 ET Copyright","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653010788","title":"Celldex reports barzolvolimab study did not meet primary, secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2653010788","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653010788?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:11","pubTimestamp":1784664682,"startTime":"0","endTime":"0","summary":"Celldex (CLDX) reported topline results from the company’s Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis, a chronic ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-reports-barzolvolimab-study-did-not-meet-primary-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-reports-barzolvolimab-study-did-not-meet-primary-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653302788","title":"Celldex Posts Press Release on Phase 2 Barzolvolimab Results in Prurigo Nodularis","url":"https://stock-news.laohu8.com/highlight/detail?id=2653302788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653302788?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:05","pubTimestamp":1784664330,"startTime":"0","endTime":"0","summary":"Celldex posts press release on Phase 2 barzolvolimab results in prurigo nodularisCelldex released Phase 2 topline data for barzolvolimab in prurigo nodularis; the study missed the primary endpoint at ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL8jVHJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653520007","title":"Celldex Therapeutics - Profound Systemic Mast Cell Depletion Observed in Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2653520007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653520007?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:01","pubTimestamp":1784664060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUA4D0RR8:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":0.0975},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1355},{"period":"6month","weight":0.7294},{"period":"1year","weight":0.7913},{"period":"ytd","weight":0.4378}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.55,"avgChangeRate":0.123409},{"month":2,"riseRate":0.425,"avgChangeRate":-0.00139},{"month":3,"riseRate":0.475,"avgChangeRate":0.004594},{"month":4,"riseRate":0.5,"avgChangeRate":0.003159},{"month":5,"riseRate":0.275,"avgChangeRate":-0.021672},{"month":6,"riseRate":0.512195,"avgChangeRate":0.146914},{"month":7,"riseRate":0.439024,"avgChangeRate":-0.012125},{"month":8,"riseRate":0.390244,"avgChangeRate":-0.026619},{"month":9,"riseRate":0.325,"avgChangeRate":-0.018185},{"month":10,"riseRate":0.5,"avgChangeRate":0.004664},{"month":11,"riseRate":0.575,"avgChangeRate":0.057317},{"month":12,"riseRate":0.45,"avgChangeRate":-0.008619}],"exchange":"NASDAQ","name":"Celldex Therapeutics","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celldex Therapeutics,CLDX,Celldex Therapeutics股票,Celldex Therapeutics股票老虎,Celldex Therapeutics股票老虎国际,Celldex Therapeutics行情,Celldex Therapeutics股票行情,Celldex Therapeutics股价,Celldex Therapeutics股市,Celldex Therapeutics股票价格,Celldex Therapeutics股票交易,Celldex Therapeutics股票购买,Celldex Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction